Vanda Pharmaceuticals Inc.
A Washington, D.C.-based biopharmaceutical company that develops medicines for brain and nervous-system conditions. Its products include Hetlioz, a treatment for a rare sleep disorder in which totally blind people's internal body clocks drift because they cannot perceive light, and Fanapt, an antipsychotic for schizophrenia. Founded in 2003 by a Greek-American scientist who worked on the Human Genome Project, the company takes its name from the Vanda, a genus of orchids.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Millennium Management LLC | 13GPassive | 5.6% | 3.38M | Aug 19, 2026 |
| Millennium Group Management LLC | 13GPassive | 5.6% | 3.38M | Aug 19, 2026 |
| Israel A. Englander | 13GPassive | 5.6% | 3.38M | Aug 19, 2026 |
| AQR Capital Management, LLC | 13GPassive | 5.82% | 3.50M | Aug 13, 2026 |
| AQR Capital Management Holdings, LLC | 13GPassive | 5.82% | 3.50M | Aug 13, 2026 |
| STATE STREET CORPORATION | 13GPassive | 5.1% | 3.02M | May 12, 2026 |
| BlackRock Portfolio Management LLC | 13G/APassive | 4.2% | 2.51M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| BlackRock, Inc. | 13G/APassive | 8.1% | 4.70M | Feb 7, 2025 |